The ASCO Annual Meeting will be held in Chicago, USA, from May 30 to June 3, 2026 (local time). Multiple research results from Chipscreen Biosciences' (Stock Code: 688321.SH) independently developed innovative drugs in the fields of colorectal cancer, lymphoma, breast cancer, and ovarian cancer have been selected.

 

Chidamide (Metastatic Colorectal Cancer)

Presentation Title:

A phase 2 study of fruquintinib combined with sintilimab and chidamide in refractory MSS metastatic colorectal cancer: Preliminary efficacy and safety.

Abstract Number: 2631

Presentation Type: Poster

First Author:

Professor Wang Chang, The First Hospital of Jilin University

Presentation Time: May 31, 2026 (US Central Time)

 

 

Chidamide (Peripheral T-Cell Lymphoma)

Presentation Title:

Chidamide in combination with CHOP in previously untreated peripheral T-cell lymphoma with T follicular helper phenotype: Results of the phase II SWIFT trial.

Abstract Number: 7082

Presentation Type: Poster

First Author:

Professor Cai Qingqing, Sun Yat-sen University Cancer Center

Presentation Time: June 1, 2026 (US Central Time)

 

 

Chidamide (Colorectal Cancer)

Presentation Title:

Chidamide combined with serplulimab and regorafenib or fruquintinib as third-line therapy for advanced colorectal cancer (C-ooperate/SCOG-C001): A single-arm, exploratory, multicenter, phase 2 trial

Abstract No.: e15583

Presentation Type: Online Publication

First Author / Presenter:

Professor Li Wei, Department of Medical Oncology, The First Affiliated Hospital of Soochow University

 

 

Chidamide (Breast Cancer)

Presentation Title:

Preliminary results of a randomized phase II trial of chidamide plus fulvestrant with or without sintilimab in HR+/HER2- advanced breast cancer after progression on CDK4/6 inhibitors (CISFORT)

Abstract No.: e13051

Presentation Type: Online Publication

First Author / Presenter:

Professor Li Haifeng, Sun Yat-sen University Cancer Center

 

Chidamide (Epidaza^®) is the world's first subtype-selective histone deacetylase (HDAC) inhibitor discovered by Chipscreen Biosciences. It belongs to the class of epigenetic regulatory drugs and is also the first original anti-tumor chemical innovative drug (National Class 1 New Drug) approved for marketing in China. It has been included in the National Reimbursement Drug List under Category B routine management.

 

Chiauranib (Ovarian Cancer)

Presentation Title:

A phase III CHIPRO study of chiauranib plus weekly paclitaxel for platinum-resistant or refractory ovarian cancer.

Abstract No.: LBA5504

Presentation Type:

LBA + Oral Abstract Session

First Author / Presenter:

Professor Wu Xiaohua, Fudan University Shanghai Cancer Center

Presentation Time: May 30, 2026 (US Central Time)

 

Chiauranib is a new molecular entity with global patent protection discovered by Chipscreen Biosciences. It is a triple-pathway tumor-targeted inhibitor.It can selectively inhibit targets such as Aurora B, CSF1R, and VEGFR/PDGFR/c-Kit, exerting broad-spectrum anti-tumor effects by inhibiting tumor cell proliferation, anti-tumor angiogenesis, and regulating the tumor immune microenvironment.